复肺解毒方联合西医标准方案治疗气阴两虚型Ⅲa～Ⅳ期驱动基因阴性非小细胞肺癌的临床观察OA

Objective To explore the clinical efficacy of Fufei Jiedu Formula combined with standard Western therapy in the treatment of stage Ⅲa～Ⅳ driver gene-negative non-small cell lung cancer(NSCLC)with qi and yin deficiency syndrome.Methods From February 2024 to February 2025,61 patients with stage Ⅲa～Ⅳ negative driver-genes NSCLC of qi and yin deficiency syndrome admitted to Tumor Hospital,Affiliated Hospital of Shaanxi University of Chinese Medicine were selected and randomly divided into a control group of 30 cases and a treatment group of 31 cases.The control group was treated with standard Western therapy.The treatment group was treated with Fufei Jiedu Formula on the basis of the control group.Each 21-day cycle was considered as one cycle,and a total of three cycles were administered.The short-term efficacy[objective response rate(ORR),disease control rate(DCR)],long-term efficacy[progression-free survival(PFS)],quality of life[quality of life questionnaire lung cancer module 30(QLQ-C30)score],traditional Chinese medicine(TCM)syndrome score and efficacy,physical status efficacy,tumor markers[carcinoembryonic antigen(CEA),squamous cell carcinoma specific antigen(SCC),cytokeratin 19 fragment(CYFRA21-1),gastrin-releasing peptide precursor(ProGRP),and neuron-specific enolase(NSE)],and safety of the two groups of patients before treatment and after 3 chemotherapy cycles were compared.Results In terms of short-term efficacy in solid tumors,the differences in ORR and DCR between the two groups were not statistically significant.There was no statistically significant difference in PFS between the two groups of patients.After treatment,the Eastern Cooperative Oncology Group Performance Status(ECOG)score,quality of life score,TCM syndrome score and efficacy,CEA,SCC,and CYFRA21-1 in the treatment group were significantly lower than those before treatment(P＜0.05).In the quality of life score of the control group,nausea and vomiting were more severe than those before treatment(P＜0.05).All the above indicators in the treatment group were significantly lower than those in the control group(P＜0.05).The incidences of leukopenia,hemoglobin reduction,neutropenia reduction,nausea,vomiting,and dyspnea in the treatment group were significantly lower than those in the control group(P＜0.05).Conclusion To a certain extent,Fufei Jiedu Formula can inhibit the trend of tumor progression,significantly improve the quality of life of patients with advanced driver gene-negative NSCLC,relieve symptoms,improve the physical status,reduce the levels of tumor markers,and lower treatment-related adverse reactions.